CJC/IPA vs Tesa/IPA: how CJC-1295 and tesamorelin differ in half-life, dosing, FDA status, and research use when each is paired with ipamorelin.
CJC/IPA and Tesa/IPA are growth hormone secretagogue stacks that share one ingredient and differ in the other. CJC/IPA pairs CJC-1295 with ipamorelin, while Tesa/IPA pairs tesamorelin with ipamorelin. The practical difference comes down to half-life, injection frequency, and regulatory status, not to two unrelated mechanisms.
This article compares the two stacks as they appear in published research and in the research-chemical market. It is educational information, not medical advice, and none of these compounds should be used without supervision from a licensed healthcare professional.
What Each Stack Contains
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). Its structure includes a drug affinity complex (DAC) that lets it bind albumin and remain active for days instead of minutes. CJC-1295 is not FDA-approved for human use.
Tesamorelin is also a GHRH analog, but it is a pharmaceutical product. It is FDA-approved under the brand name Egrifta for a narrow indication: excess abdominal fat in people living with HIV who have lipodystrophy. It is not approved as a general anti-aging or body-composition drug.
Ipamorelin appears in both stacks. It is a short pentapeptide that acts on the ghrelin receptor and is often described as one of the more selective GH secretagogues studied, with less impact on cortisol, prolactin, and appetite than older ghrelin mimetics in early research.
CJC-1295 vs Tesamorelin: The Core Difference
The two GHRH analogs are not interchangeable, and the half-life gap is the main reason. Anyone weighing cjc-1295 ipamorelin vs tesamorelin is really comparing an extended-duration research peptide against a shorter-acting prescription drug.
| Feature | CJC-1295 with DAC | Tesamorelin |
|---|---|---|
| Class | GHRH analog with albumin-binding DAC | Stabilized GHRH analog |
| Approximate half-life | Days (roughly 6-8 days reported) | Under an hour (roughly 26-38 minutes reported) |
| Typical research frequency | Once or twice weekly | Once daily |
| FDA approval for human use | No | Yes, for HIV-associated lipodystrophy |
| Availability | Research-chemical market | Prescription pharmacy |
The choice between CJC-1295 with DAC and without is a separate question. If you are researching cjc-1295 dac vs no dac, keep in mind that the DAC version lasts days while the unmodified version behaves much more like tesamorelin in duration.
Stack-Level Comparison: CJC/IPA vs Tesa/IPA
When the GHRH analog is paired with ipamorelin, the differences narrow but do not disappear. Ipamorelin dosing stays the same; only the frequency of the GHRH component changes.
| Factor | CJC/IPA | Tesa/IPA |
|---|---|---|
| Shared ingredient | Ipamorelin | Ipamorelin |
| GHRH component | CJC-1295 | Tesamorelin |
| Injection frequency | Lower (weekly CJC-1295 with DAC) | Higher (daily tesamorelin) |
| Prescription required | No legal prescription pathway in the US | Yes, for the labeled indication |
| Human clinical trial data | Limited | Extensive for the approved indication |
Some suppliers market a tesa ipa cjc blend that puts all three peptides in a single vial. That format raises additional questions about ratio accuracy, sterility, and labeling that a researcher cannot verify from the outside.
Where Ipamorelin Fits in Both Stacks
Ipamorelin is the constant in this comparison, so it does not explain the difference between the stacks. Researchers pair it with a GHRH analog because the two act on different receptors and are studied for a complementary effect on GH release.
It is also worth separating the two compounds conceptually. Some people search for cjc-1295 vs ipamorelin as though one could replace the other, but they target different receptors and are usually studied together rather than head-to-head.
Dosing and Timing in Research Protocols
Published research and product labeling use different schedules for each compound. The figures below describe what appears in the literature and in the approved prescribing information, not personal dosing advice.
- CJC-1295 with DAC: studied at roughly 1-2 mg per week, often split into one or two injections.
- CJC-1295 without DAC (Mod GRF 1-29): studied at about 100 mcg per dose, two or three times daily.
- Tesamorelin: the approved product is injected subcutaneously once daily at the labeled dose.
- Ipamorelin: commonly studied at 100-200 mcg per dose, sometimes two or three times daily, typically separated from food.
Shorter-acting GHRH analogs follow a similar daily rhythm, which is why comparisons such as cjc-1295 vs sermorelin tend to focus on duration of action rather than on fundamentally different biology.
FDA Approval and Legal Status
Tesamorelin is the only compound in either stack with FDA approval for human use. That approval is narrow and tied to a specific diagnosis, which means it is not available as a general wellness or performance product.
CJC-1295 and ipamorelin are not FDA-approved for human use in the United States. Products sold online are usually labeled "for research purposes only," and no regulator verifies their purity, concentration, or sterility.
This legal difference is often more consequential than any pharmacological detail. A clinician can prescribe tesamorelin for its labeled indication; the same is not true for CJC-1295 or ipamorelin.
Safety Considerations
Reported side effects in the tesamorelin literature include injection-site reactions, joint pain, peripheral swelling, and changes in blood sugar. Because GHRH analogs and ghrelin mimetics influence the endocrine system, unsupervised use carries real risk.
People with diabetes, a history of cancer, pituitary disease, or who are pregnant or breastfeeding should be especially cautious and should speak with a healthcare professional before considering any of these compounds.
In clinical use of tesamorelin, markers such as blood sugar and IGF-1 are monitored over time. A similar level of oversight would be reasonable in any supervised setting.
The Bottom Line
There is no universally better stack. CJC/IPA offers a longer-acting GHRH component and fewer injections in research settings, while Tesa/IPA uses a compound with an FDA-approved label and far more human data.
The shared ingredient, ipamorelin, means the decision usually hinges on how often you are willing to inject, how important regulatory status is to you, and how much published human evidence you want behind the GHRH component.
Frequently Asked Questions
Is CJC/IPA or Tesa/IPA better?
Neither stack is universally better. Tesa/IPA contains tesamorelin, the only compound in either stack with FDA approval, but that approval covers a narrow diagnosis rather than general body-composition use. CJC/IPA is studied with a longer-acting GHRH analog, which usually means fewer injections in research protocols, but CJC-1295 is not FDA-approved for human use.
Is tesamorelin the same as CJC-1295?
No. Both are GHRH analogs, but they are different molecules with very different durations of action. CJC-1295 with DAC has a reported half-life of several days, while tesamorelin's reported half-life is under an hour. That gap is why tesamorelin is dosed daily and CJC-1295 with DAC is studied on a weekly schedule.
Can you stack CJC-1295, tesamorelin, and ipamorelin together?
Combining two GHRH analogs such as CJC-1295 and tesamorelin is redundant because both act on the same receptor, and there is no clinical data supporting the combination. Some vendors sell blended vials, but the ratios, sterility, and labeling of those products are not verified by any regulator. Anyone considering these compounds should consult a licensed healthcare professional first.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.